• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

24

CATEGORIES

  • 17
  • 13
  • 7
  • 7
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

22
28
36
63

PUBLISHED

0
3
11
63

PRODUCT TYPE

48
15

Search "Santaris Pharma A/S" returned 63 results.

Santaris Pharma A/S - Product Pipeline Review - H2 2011

Santaris Pharma A/S – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - H2 2011” provides data on the Santaris...

November 2011
FROM

Santaris Pharma A S - Product Pipeline Review - Q4 2010

Santaris Pharma A S – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - Q4 2010” provides data on the company’s...

November 2010
FROM

Santaris Pharma A S - Product Pipeline Review - Q4 2010

Santaris Pharma A S – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - Q4 2010” provides data on the company’s...

November 2010
FROM

Global RNA Interference (RNAi) Therapy Market Outlook 2018

The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery Over the years this technology has become an integral...

March 2014
FROM

Global MicroRNA Market 2012-2016

The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research...

September 2013
FROM

PCSK9 Inhibitors - The hot new approach to lower cholesterol

Several companies are actively pursuing a new strategy to lower cholesterol: the inhibition of the PCSK9 gene/enzyme This enzyme speeds the degradation of LDL receptors Thus its inhibition should preserve...

October 2012
FROM

Global Hypercholesterolemia Market 2014-2018

About Hypercholesterolemia Hypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood High cholesterol levels, in turn,...

June 2014
FROM

Competitor Analysis: Targeted Therapy of Hepatitis C

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C)...

August 2011
FROM

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma

“Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma” provides insights into the unmet needs in the pharmaceutical and healthcare market and potential segments where...

February 2010
FROM
miRNA Research and Diagnostics Markets miRNA Research and Diagnostics Markets - Product Thumbnail Image

miRNA Research and Diagnostics Markets

miRNA Research and Diagnostics Markets This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs.  miRNAs (MicroRNAs) are short, single stranded...

September 2014
FROM
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities - Product Thumbnail Image

Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities

This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines It provides opinions & market projections to: - assess the commercial potential of RNAi-based...

July 2009

Global miRNA Market 2015-2019

About miRNAs miRNAs are single-stranded, small, non-coding RNA molecules that regulate gene expression at the translation level. They play a vital role in research, diagnostics, and therapeutics to...

November 2014
FROM

BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030

Several people across the globe suffer from different neurological disorders. However, the drugs currently available in the market provide only symptomatic relief and do not treat the root cause. This...

May 2015
FROM
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class? Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class? - Product Thumbnail Image

Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

This report gives you a new and unique way of stratifying and analyzing the global melanoma pipeline and presents actionable analysis which allows you to discover: - Where the competition is; Which...

June 2013
FROM

PCSK9 and Other Novel Hypercholesterolemia Drugs

Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously...

September 2014
FROM

Hypercholesterolemia - Pipeline Review, H2 2013

Hypercholesterolemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hypercholesterolemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

September 2013
FROM

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014 Summary This, ‘Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014’, provides an overview of the Multiple Myeloma (Kahler's...

September 2014
FROM

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014 Summary This, ‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014’, provides an overview of the Head And...

September 2014
FROM

Gynecological Cancer - Pipeline Review, H1 2013

Gynecological Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

May 2013
FROM

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

This report comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 companies, from Ceased to Marketed The report extensively analyses their...

March 2011
FROM
Loading Indicator

Our Clients

Glanbia Plc. Unilever N.V. Microsoft Corporation Duke University A.T. Kearney PepsiCo Inc. Boston Consulting Group